전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
no subject
bez temata
마지막 업데이트: 2012-02-15
사용 빈도: 4
품질:
(no subject)
(no subject)
마지막 업데이트: 2018-02-13
사용 빈도: 1
품질:
no subject specified
nav norādīts temats
마지막 업데이트: 2011-10-23
사용 빈도: 3
품질:
10:49p (no subject)
temats:
마지막 업데이트: 2018-02-13
사용 빈도: 6
품질:
(no subject) @ 02:11 pm
temats:
마지막 업데이트: 2018-02-13
사용 빈도: 1
품질:
no subject had a qtcf >450 msec.
nevienam dalībniekam nebija qtcf >450 ms.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
경고: 보이지 않는 HTML 형식이 포함되어 있습니다
11:15a (no subject) - 1 reply
temats:
마지막 업데이트: 2018-02-13
사용 빈도: 1
품질:
no subject received a blood transfusion.
nevienam dalībniekam netika pārlietas asinis.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
12:10 pm: (no subject) - 1 comment
1.
마지막 업데이트: 2018-02-13
사용 빈도: 1
품질:
no subject discontinued the studies due to adverse events.
neviens pacients nepārtrauca pētījumu blakusparādību dēļ.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
no subject discontinued the study due to an adverse event.
neviens pacients blakusparādību dēļ nepārtrauca dalību pētījumā.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
no subject in either group showed emergence of protease inhibitor resistance.
nevienam no abu grupu pacientiem neradās proteāzes inhibitoru rezistence.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
no subject in any group had an increase in qtc of ≥60 msec from baseline.
nevienam subjektam nevienā no grupām netika konstatēts qtc pagarinājums par – 60 ms salīdzinājumā ar sākumstāvokli.
마지막 업데이트: 2017-04-26
사용 빈도: 5
품질:
no subject experienced an interval exceeding the potentially clinically relevant threshold of 500 msec.
nevienam no subjektiem netika sasniegts potenciālais klīniskais slieksnis, proti, 500 ms.
마지막 업데이트: 2017-04-26
사용 빈도: 4
품질:
no episodes of major hypoglycaemia were reported, and no subject discontinued the study treatment due to hypoglycaemia.
par smagas hipoglikēmijas gadījumiem netika ziņots, un hipoglikēmijas dēļ pētāmo zāļu lietošanu nepārtrauca neviens pacients.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
no subject experienced an increase in qtcf of 60 msec from baseline or a qtcf interval exceeding the potentially clinically relevant threshold of 500 msec.
nevienam dalībniekam qtcf nepalielinājās par 60 msec no sākotnējā vai qtcf intervāls nepārsniedza potenciāli klīniski nozīmīgo 500 msec slieksni.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
no subject experienced an increase in qtcf of ≥ 60 msec from baseline or a qtcf interval exceeding the potentially clinically relevant threshold of 500 msec.
nevienam no subjektiem qtcf nepalielinājās ≥ 60 msec, salīdzinot ar sākumstāvokli, un qtcf intervāls nepārsniedza potenciāli klīniski nozīmīgo 500 msec slieksni.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
we agreed to discuss nuclear issues and we accepted that these are a subject to be debated between us, because it was made clear from the beginning that no subject was taboo.
mēs piekritām apspriest kodolenerģijas jautājumus, un mēs piekritām, ka tā ir tēma, kas apspriežama starp mums, jo bija skaidrs jau no paša sākuma, ka neviena tēma nav tabu.
마지막 업데이트: 2012-03-01
사용 빈도: 4
품질:
we must have a challenging dialogue with china where no subject is taboo, and we must encourage it to make commitments in all areas, in the political, human rights and social fields.
mums ir jārisina stimulējošs dialogs ar Ķīnu, kur neviens temats nav tabu, un mums tā ir jāmudina uzņemties saistības visās jomās - politiskajā, cilvēktiesību un sociālajā.
마지막 업데이트: 2012-03-01
사용 빈도: 4
품질:
no subjects developed new clinically relevant ecg morphological changes following administration of amifampridine phosphate.
pēc amifampridīna fosfāta lietošanas jaunas, klīniski nozīmīgas morfoloģiskas izmaiņas ekg neattīstījās nevienam pacientam.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질: